Loading quotes...
Forecast
| Buy |
1 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
Berenberg raises price target for Fresenius to €54 and affirms 'Buy'
Berenberg has raised the price target for Fresenius from €50 to €54 and maintained the 'Buy' rating. Analyst Harry Gillis views the market valuation as too conservative, expects mid‑term high-single-digit annual EPS growth and sees his 2027 forecast two percent above consensus. Management has lifted the outlook four times in the past two years, so the bank sees further upside in consensus estimates. » More on finanzen.net
Fresenius SE: ten-year investment would have resulted in 35.69% loss
Someone who invested EUR 10,000 in Fresenius SE ten years ago would now own around 142.918 shares, whose last closing price of EUR 45.00 reduced the portfolio value to EUR 6,431.33. That corresponds to a loss of 35.69%. Market capitalization was most recently EUR 25.29 billion. Stock splits and dividends are not included in the calculation. » More on finanzen.net
Fresenius ahead of quarterly results: JPMorgan and Deutsche Bank remain positive
JPMorgan confirms Fresenius as a favorite and keeps the rating at "Overweight" with a price target of €55.20 after talks with the investor-relations department. Deutsche Bank keeps the rating at "Buy" with a price target of €56 and expects organic sales growth of around 5% as well as adjusted EPS growth of about 12%; the full-year guidance could also be slightly raised. Chart-wise, the stock has reclaimed the 200-day line and is approaching the August high at €48.48; a stop is cited at €34.50. » More on deraktionaer.de
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 5.95B | 6.52% |
| Gross profit | 1.55B | 6.31% |
| Net profit | 382M | 15.76% |
| EBITDA | 882M | 4.38% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €25.97B |
Number of shares | 563.24M |
52-week high/low | €52.96 - €35.11 |
| Dividends | No |
Beta | 0.82 |
P/E ratio | 16.76 |
PEG ratio | 0.46 |
P/B ratio | 1.32 |
P/S ratio | 1.11 |
Company profile
Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
| Name | Fresenius |
| CEO | Michael Sen |
| Headquarters | Bad Homburg vor der Höhe,
he Germany |
| Website | |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| IPO | 11/09/1998 |
| Employees | 178,486 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
XETRA | FRE.DE |
Pnk | FSNUF |
SIX | FRE.SW |
Frankfurt | FRE.F |
Düsseldorf | FRE.DU |
Hamburg | FRE.HM |
Milan | 1FRE.MI |
London | 0OO9.L |
München | FRE.MU |
Wien | FRE.VI |